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Traumatic brain injury (TBI) is an important and costly medical problem for which
no clinically proven treatment currently exists. Studies in rodents and humans have
shown beneficial effects of progesterone (P4) on both mortality and functional outcomes
following TBI. Neuroprotective effects of P4 in TBI likely involve the classical nuclear
progesterone receptors (Pgr) that are widely distributed in both glial cells and neurons
of the brain. However, P4 may have critical effects not mediated through Pgr. In the
brain, P4 is converted to a metabolite, allopregnanolone (ALLO), whose beneficial effects
equal or exceed those of P4 in TBI. ALLO does not bind Pgr, suggesting it acts through
non-classical pathways. ALLO has effects on GABAA and pregnane X receptors, as well
as on the mitochondrial permeability transition pore. In addition, ALLO is metabolized
to another compound, 5alpha-dihydroprogesterone, which binds Pgr, suggesting ALLO
actions may involve signaling through Pgr as well as the aforementioned mechanisms of
action. P4 and ALLO also signal through a number of membrane receptors (progesterone
receptor membrane component 1, and membrane progesterone receptors (mPRs) alpha,
beta, gamma, delta, and epsilon) in the brain that are distinct from Pgr, although the role
of these receptors in the normal brain and in the therapeutic response to P4 and ALLO
following TBI is unclear. In summary, P4 has the potential to become the first clinically
effective treatment for TBI, and the effects of P4 and its metabolite ALLO in TBI may
involve Pgr, mPRs, and other signaling pathways. Elucidating these mechanisms will more
clearly reveal the potential of classical and non-classical pathways to mediate important
effects of P4 and its metabolites, and potentially offer new therapeutic approaches to TBI.
Keywords: progesterone receptor, membrane receptors, allopregnanolone, progesterone receptor membrane
component 1, controlled cortical impact
INTRODUCTION
Traumatic brain injury (TBI) is defined as a neurotrauma result-
ing from a mechanical force, such as that caused by rapid
acceleration or deceleration, blast waves, crush, an impact, or
penetration by a projectile. TBI is a major cause of death and dis-
ability worldwide, especially in children and young adults. The
Centers for Disease Control and Prevention (CDC) estimate that
there are approximately 1.4–2.0 million incidents each year in
the U.S. involving TBI. Of these, nearly 100,000 patients die,
another 500,000 are hospitalized, and thousands of others suf-
fer short- and long-term disabilities. Leading causes of TBI in the
Abbreviations: ALLO, allopregnanolone (3α-hydroxy-5α-pregnan-20-
one); CDC, Centers for Disease Control and Prevention; 5α-DHP,
5α-dihydroprogesterone; 3β-HSD, 3β-hydroxysteroid dehydrogenase; GABA,
γ-amino butyric acid; mPR, membrane progesterone receptor; MPTP, mitochon-
drial permeability transition pore; PXR, pregnane X receptor; P4, progesterone;
PRKO, progesterone receptor knockout; Pgr, progesterone receptor; PGRMC1,
progesterone receptor membrane component 1; ProTECT, Progesterone for the
Traumatic Brain Injury, Experimental Clinical Treatment; TBI, traumatic brain
injury.
U.S include violence, transportation accidents, construction, and
sports. Falls account for the greatest number of TBI cases (34%),
with motor vehicle crashes and traffic-related incidents (17%),
struck by/against events (16%), and events and assaults (10%)
also being important contributors (Faul et al., 2010). CDC esti-
mates of TBI do not include injuries seen at U.S. Veterans Health
Administration Hospitals. Firearms and blast injuries from explo-
sions are major causes of TBI. Among the 1.6 million American
warfighters returning from Iraq and Afghanistan, between 5 and
35% sustained a mild TBI or concussion during their deploy-
ment, with 80% being caused by blast exposures (Champion et al.,
2009).
A wide variety of treatments have been and are currently used
for TBI, including diuretics such as mannitol to reduce intracra-
nial pressure, hypothermia and medically induced coma. In cases
where intracranial pressure remains high for an extended period
of time, surgical interventions such as decompressive craniectomy
are commonly used (Maas et al., 2008). However, although all of
these methods may have potential benefits, and in some cases are
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widely used, no treatment has been shown to have clear bene-
fits in any of the large number of randomized clinical trials that
have been conducted (Maas et al., 2008). Therefore, despite the
prevalence of TBI, there presently are no clinically proven effective
treatments.
Progesterone (P4) and its metabolites have shown great
promise as potential treatments for TBI. Progesterone is an ovar-
ian steroid hormone that regulates many facets of reproduction
(Lydon et al., 1995; Conneely et al., 2001). Over the past two
decades, an increasing body of literature (reviewed in Sayeed and
Stein, 2009; Stein andWright, 2010; Stein, 2012) has documented
the remarkable beneficial effects of P4 onmortality andmorbidity
following TBI. These treatments were originally developed using
animal models that replicate the various aspects of human TBI
pathophysiology, such as the controlled cortical impact injury
model utilized extensively in rats and mice. More recent results
have indicated that this treatment may show equal promise in
human patients following TBI (Sayeed and Stein, 2009; Stein and
Wright, 2010; Stein, 2012).
The initial presumption is that beneficial P4 effects following
TBI aremediated through classical nuclear progesterone receptors
(Pgr). However, identification of several membrane progesterone
receptors (mPR) that are ubiquitously expressed in the brain
(Meffre et al., 2005; Intlekofer and Petersen, 2011; Pang et al.,
2013) and the demonstration that allopregnanolone (ALLO), a
P4 metabolite that does not bind Pgr, had effects in TBI mod-
els equaling or exceeding those of P4 [reviewed in Sayeed et al.
(2009)] calls this into question. Here we review current under-
standing of themechanism of action of P4 andmetabolites in TBI,
with an emphasis on non-Pgr mediated pathways. Complete elu-
cidation of how P4 and related compounds work could present
new possibilities for improving P4 therapy or developing second-
generation treatments for TBI.
PROGESTERONE PRODUCTION AND FUNCTION IN BRAIN
The term neurosteroid was coined by Baulieu in 1981 to describe
steroids produced in the brain as a result of de novo synthesis
or metabolism of steroid precursors from the peripheral circula-
tion that alter the activity of neurons or other cells types (Baulieu,
1981). Progesterone is a neurosteroid, and is produced in both
glial and neuronal cells of the CNS (Baulieu et al., 2001).
Nuclear Pgr, like other steroid hormone receptor superfamily
members, is a ligand-activated transcription factor and is widely
distributed throughout female reproductive organs. Reproductive
and non-reproductive organs in males also express Pgr (Shughrue
et al., 1988). In both sexes, Pgr concentrations are high in
hypothalamic regions regulating reproductive cyclicity, and occur
throughout the brain of both mature and developing animals.
Almost all brain areas express Pgr, although clear regionalities
in relative amounts are observed (Intlekofer and Petersen, 2011).
Various cell types, including neurons, glia, and other cell types
(reviewed in Brinton et al., 2008) express Pgr, indicating that most
brain cells are potential P4 targets.
The exact role of P4 signaling in non-reproductive brain
areas is unclear. Actions of P4 and metabolites in the brain are
pleiotropic, and its effects on Schwann cell proliferation and
myelination, memory, cognition, neural excitability, glial cell
function, inflammation, neurogenesis and neural progenitor cell
proliferation are well-known (Brinton et al., 2008). In addition to
its extensive roles in brain, P4 effects on pathologies as diverse as
Alzheimer’s disease, stroke and post-traumatic stress disorder, as
well as TBI, have been documented or suggested (Brinton et al.,
2008).
PROGESTERONE EFFECTS IN ANIMAL MODELS OF TBI
Work using animal models has shown that P4 and its metabolite
ALLO produce a remarkable array of beneficial short- and long-
term effects following TBI (Table 1). The neuroprotective role of
P4 was first reported by Stein and colleagues (Roof et al., 1992,
1993), who showed that female rats recovered better than males
did following TBI. Subsequent hormone replacement experi-
ments indicated that P4 was similarly neuroprotective in males
and females following TBI (Roof et al., 1994). These initial find-
ings were confirmed and expanded by many different groups
using a variety of TBI models (Sayeed and Stein, 2009; Stein and
Wright, 2010; Stein, 2012; Table 1). Progesterone and its metabo-
lite ALLO are effective in reducing the brain swelling and edema
that are TBI hallmarks, and P4 has beneficial effects on blood
brain barrier function and intracranial pressure following TBI
(Ishrat et al., 2010). P4 ameliorates the increases in inflammatory
cytokines such as TGF-β, TNF-α, IL-6, and IL-1β that occur after
TBI (He et al., 2004a,b), decreases gliosis and apoptosis (Djebaili
et al., 2004, 2005; He et al., 2004b), and increases expression
of anti-oxidant enzymes such as superoxide dismutase (Pajovic´
et al., 1996). Most critically, the beneficial effects occurring in the
first few days following TBI are also accompanied by significant
improvements in long-term deficits in cognition and function-
ality normally experienced by animals after TBI (Djebaili et al.,
2004, 2005; Espinoza and Wright, 2011; Stein, 2012). For exam-
ple, P4 administration to rats following TBI led to improved
locomotor activity and performance on the Morris water maze
test used to assess learning and spatial memory (Djebaili et al.,
2004, 2005; He et al., 2004a,b). More recently, P4 has been
reported to decrease anxiety following TBI (Djebaili et al., 2005).
Overall, these studies clearly showed that P4 improved cognitive
and behavioral recovery, the primary goal of any neuroprotective
agent.
PROGESTERONE EFFECTS IN HUMAN CLINICAL TRIALS
The success of initial animal studies led to human clinical tri-
als to determine if P4 could produce similar benefits in humans.
Progesterone was shown to be neuroprotective for humans fol-
lowing TBI in two small-scale pilot studies and is presently being
tested in more extensive phase III clinical trials for moderate to
severe TBI (Stein, 2012). A pilot study funded by NIH called
Progesterone for Traumatic Brain Injury, Experimental Clinical
Treatment (ProTECT) was a 3-year, randomized, double-blind,
placebo-controlled phase 1 and 2 trial, with a total of 100 adult
TBI patients. Progesterone was found to be safe and produced no
adverse events in the participants. Among 77 patients receiving
progesterone and 23 receiving placebos, P4 reduced the over-
all death rate by 50% compared with placebo, with significant
improvements in functional outcomes and level of disability
among patients with brain injury (Wright et al., 2007; Table 1).
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Table 1 | Representative effects of progesterone (P4) and allopregnanolone (ALLO) treatment following traumatic brain injury.
Treatment Species Effect References
P4, ALLO Rat Decrease in inflammatory cytokines (e.g., IL-Iβ, TNF-α) He et al., 2004a; VanLandingham et al., 2006; Anderson
et al., 2011
P4, ALLO Rat, Mouse Improved spatial learning performance in Morris Water Maze Roof et al., 1994; Goss et al., 2003; Djebaili et al., 2004;
He et al., 2004a; Jones et al., 2005; Roof et al., 2005
P4, ALLO Rat Decreased apoptosis and neuronal death Roof et al., 1992; Djebaili et al., 2004; He et al., 2004a;
VanLandingham et al., 2006; Anderson et al., 2011
P4, ALLO Rat Decreased reactive gliosis Goss et al., 2003; Djebaili et al., 2005; VanLandingham
et al., 2006
P4, ALLO Rat Decreased edema Roof et al., 1992; VanLandingham et al., 2006; Kasturi and
Stein, 2009
P4 Rat Decreased impairment of blood-brain barrier Cutler et al., 2007; Ishrat et al., 2010
P4 Rat Decreased expression of proapoptotic proteins Djebaili et al., 2005
ALLO Human, Rat Increased proliferation of neural progenitor cells Wang et al., 2005
P4, ALLO Rat Decreased anxiety following TBI Cutler et al., 2006; Baykara et al., 2013
ALLO Rat Decreased mitochondrial damage Kaasik et al., 2003; Sayeed et al., 2009
P4 Rat Increased expression of brain-derived neurotrophic factor
(BDNF)
Cutler et al., 2006
P4, ALLO Rat Increased signaling through GABAA receptors, with
decreased neuronal excitotoxicity
He et al., 2004a
P4 Rat Decreased intestinal inflammatory response Chen et al., 2008
P4 Human Decreased mortality, improved functional outcomes Wright et al., 2007; Xiao et al., 2008
A concurrent trial of P4 in China utilizing 159 TBI patients also
showed that P4 significantly lowered the mortality rate and pro-
duced improved functional outcomes (Xiao et al., 2008; Table 1).
These promising results led to the design and initiation of
ProTECT III, a currently on-going NIH-funded phase III clinical
trial evaluating P4 for TBI treatment in a larger patient popu-
lation (ProTECT III, 2009). This national study began enrolling
patients in 2009 and is a multicenter, randomized, double-blind
study involving 1,140 patients over 5 years at 17 U.S. medical cen-
ters. Another phase III trial (1180 patients) sponsored by BHR
Pharma LLC (the SyNAPSe trial) is also underway to evaluate the
effectiveness of a proprietary progesterone formulation in treating
severe TBI.
ARE CRITICAL EFFECTS OF PROGESTERONE AND ALLO IN
TBI MEDIATED BY NON-CLASSICAL SIGNALING
PATHWAYS?
Actions of P4 in reproduction are mediated in large part by the
classical nuclear receptor, Pgr, as shown by infertility and loss
of most P4 functions in female progesterone receptor knockout
(PRKO) mice lacking nuclear Pgr (Lydon et al., 1995; Conneely
et al., 2001; Jeong et al., 2005). Despite the centrality of Pgr to P4
function, some studies suggest effects of P4 in the brainmight not
be solely due to binding to Pgr.
Ciriza et al. (2006) showed that the synthetic progestin
medroxyprogesterone acetate, which has high affinity for Pgr and
high potency as a progestin for most endpoints, was not neu-
roprotective. Conversely, VanLandingham et al (VanLandingham
et al., 2006) demonstrated that an enantiomer of P4 did not
activate Pgr-mediated transcription but still had neuroprotective
effects.
Several lines of evidence have suggested that beneficial effects
of P4 in TBImay be partially or even entirely due tometabolites of
P4 produced in the brain, rather than the parent molecule itself.
Extensive data indicates that the major brain metabolite of P4,
ALLO, may be signaling in large part through pathways other than
Pgr and that membrane receptors may be significant factors in
mediating therapeutic effects of both P4 and ALLO (Figure 1).
Allopregnanolone is a metabolite of P4 that is produced in the
brain (Baulieu, 1981; Baulieu et al., 2001) and may have critical
roles as a neurosteroid in both normal brain and in therapeutic
responses to P4 treatment after TBI (Table 1). Allopregnanolone
is produced from P4 by the sequential action of two steroido-
genic enzymes (Figure 1). Progesterone is first converted to
5α-dihydroprogesterone (5α-DHP) by type 1 5α-reductase. The
5α-DHP is then further converted to ALLO by 3β-hydroxysteroid
dehydrogenase (3β-HSD) (Nin et al., 2011; Wang, 2011). Both
5α-reductase and 3β-HSD are expressed at highest levels in
neurons, with minimal expression in glial cells (Agís-Balboa
et al., 2006), suggesting that ALLO production is at least pre-
dominately from neurons, although ALLO could have paracrine
actions on other brain cells. Critically, Ciriza et al (Ciriza et al.,
2006) demonstrated that inhibiting normal metabolism of P4
to 5α-DHP and ALLO abolished the neuroprotective effects of
P4. These results suggest that metabolites of P4 may play key
roles in neuroprotective effects of P4, and that the mechanism
of action of these compounds may not be exclusively through
nuclear Pgr.
Extensive work demonstrated that ALLO is highly neuropro-
tective in TBI animal models, with beneficial effects equaling or
exceeding those obtained with P4 (Table 1). Administration of
ALLO to rats following TBI reduced the increase in inflammatory
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FIGURE 1 | Potential mechanisms by which progesterone and its
metabolites signal in the brain to produce beneficial effects
following traumatic brain injury. Progesterone, either from the
systemic circulation or produced locally in the brain, can bind and signal
through the classical nuclear progesterone receptors, but also binds
receptors in the plasma membrane, including PGRMC1 and a family (α–ε)
of membrane progesterone receptors (mPRs). In addition, progesterone
can be converted to 5α-dihydroprogesterone (5α-DHP) and then
allopregnanolone in the brain. Allopregnanolone can bind and alter ion
flux through GABAA receptors, and also binds pregnane X receptors
(PXR), although the native progesterone does not bind GABAA receptors
and has limited affinity for PXR. In addition, although allopregnanolone
does not bind to nuclear progesterone receptors, it can be converted to
5α-DHP, which does have affinity for nuclear progesterone receptor.
Allopregnanolone also binds to mPRs, although its affinity for PGRMC1
has not been reported. Thus, a variety of nuclear and membrane
receptors may be involved in the beneficial effects of progesterone and
its metabolites following traumatic brain injury.
cytokines and apoptotic cell death in the brain and the functional
deficits in cognition and memory typically seen following TBI
(Djebaili et al., 2004, 2005; He et al., 2004a,b).
Critically, ALLO does not bind to the nuclear Pgr (Figure 1)
that is the major target of P4 (Rupprecht et al., 1993), suggesting
that ALLO could have independent actions differing from those of
P4. The ALLO generated by conversion of P4 to ALLO (Figure 1)
can be partially metabolized back to 5α-DHP in vivo, and this
5α-DHP binds nuclear Pgr and induces transcriptional changes
typical of P4 (Rupprecht et al., 1993). Based on its ability to be
metabolized to 5α-DHP, it seems possible that ALLO actions in
TBI are at least predominately mediated through nuclear Pgr.
Recent groundbreaking work by Liu et al. (2012) has sug-
gested, however, that neuroprotective effects of ALLO may be
independent of Pgr. This group used PRKO mice to test the neu-
roprotective effects of P4 in a stroke model. They reported that
ALLO had beneficial neuroprotective effects in PRKO mice sub-
jected to experimental stroke, while P4 was ineffective. These
results emphasize that Pgr is obligatory for protective effects of
P4 in stroke. Importantly, these results also indicate that ALLO
actions can occur in mice lacking Pgr, strongly supporting the
idea that beneficial ALLO actions are predominately independent
of Pgr (Liu et al., 2012).
MECHANISM OF ALLO ACTIONS IN TBI
If ALLO activity is independent of Pgr, determining how ALLO
acts could potentially have significance for clinical TBI treatment.
A variety of mechanisms have been suggested, including bind-
ing to GABAA receptors, mPRs, and nuclear receptors such as
pregnane X receptor (PXR).
EFFECTS THROUGH γ-AMINO BUTYRIC ACID TYPE A
(GABAA) RECEPTORS
The GABAA receptor is a ligand-gated ion channel. Upon bind-
ing to ligands such as GABA, the GABAA receptor selectively
conducts chloride ion into cells, causing hyperpolarization that
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inhibits neurotransmission. GABAA receptors are expressed in
both neurons and glial cells distributed throughout the brain
(Pirker et al., 2000). ALLO at nanomolar concentrations binds
to GABAA receptors and potentiates the action of endogenous
GABA, whereas at micromolar concentrations ALLO directly
activates GABAA receptors (Figure 1), and thus may be able
to reduce neuronal death following TBI or other insults (Paul
and Purdy, 1992; Lambert et al., 2001; Magnaghi et al., 2006).
For example, P4 and ALLO protect cerebellar Purkinje cells
in vitro and in vivo from ischemia (Ardeshiri et al., 2006;
Kelley et al., 2008, 2011). Furthermore, P4 effects were medi-
ated by ALLO acting through GABAA receptors: treatment with
finasteride, a 5α-reductase inhibitor that prevents metabolism
of P4 to ALLO, abolished the protective effects of P4 while
administration of a GABAA receptor antagonist abolished neu-
roprotective effects of both P4 and ALLO (Ardeshiri et al.,
2006).
ALLO stimulates neural progenitor proliferation (Wang et al.,
2005; Wang and Brinton, 2008) and neurogenesis of cerebel-
lar granule cells (Keller et al., 2004) and decreases neuronal cell
death, and all of these effects appear to be through GABAA
receptors. Interestingly, ALLO showed similar neuroprotective
effects through activation of GABAA receptors in PRKO and wild-
type mice after spinal cord injury (Labombarda et al., 2013).
Furthermore, ALLO has anxiolytic, anticonvulsant and anesthetic
properties believed to be mediated through GABAA receptors and
potentially involved in its effects on TBI. These effects do not
require Pgr, because ALLO effects on these endpoints were sim-
ilar in wild-type and PRKOmice (Reddy et al., 2004, 2005; Reddy
and Zeng, 2007).
ALLO EFFECTS MEDIATED THROUGH PXR
The PXR is a promiscuous receptor activated by diverse group
of endogenous or exogenous compounds, including steroids
(Lamba et al., 2004; Ma et al., 2008). PXR is expressed in vari-
ous parts of the brain and spinal cord (Lamba et al., 2004; Mellon
et al., 2008), including human cerebral microvessel endothelial
cells that form the blood brain barrier (Chan et al., 2011).
ALLO activates mouse PXR in vivo and in vitro (Figure 1)
and induces PXR target genes (Lamba et al., 2004; Langmade
et al., 2006). PXR activation is known to mediate anti-
inflammatory activities in the intestine (Mencarelli et al., 2010)
and anti-apoptotic activities in the liver (Zucchini et al., 2005).
Neuroprotective effects of ALLO after TBI involving anti-
inflammatory, anti-apoptotic effects or other actions may be
partially mediated through PXR in brain or other organs. The
use of brain-specific or global PXR knockout mice in TBI stud-
ies will clarify the role of PXR in neuroprotective effects of ALLO
after TBI.
A variety of other ALLO targets in TBI have also been pro-
posed, including the mitochondrial permeability transition pore
(MPTP). The MPTP plays a major role in initiating necrosis or
apoptosis in the brain following TBI (Crompton, 1999), and neu-
roprotective effects of ALLO may be partially mediated through
stabilization of MPTP (Kaasik et al., 2003; Sayeed et al., 2009).
Understanding interactions between ALLO and MPTP will be
essential for completely elucidating its mechanism of action and
determining whether ALLO can have significant beneficial effects
in TBI that are additive or partially additive to those seen with P4.
ROLE OF MEMBRANE PROGESTERONE RECEPTORS (mPRs) IN
THERAPEUTIC EFFECTS OF P4 AND ALLO
Several mPRs have been described, and some evidence suggests
these could be involved in therapeutic effects of P4 and/or ALLO
following TBI (Figure 1). Progesterone receptor membrane com-
ponent 1 (PGRMC1), originally cloned in 1996 from porcine liver
(Falkenstein et al., 1996), is widely expressed in brain (Meffre
et al., 2005; Guennoun et al., 2008; Intlekofer and Petersen,
2011) and increased following brain injury (Guennoun et al.,
2008). PGRMC1 is expressed in regions involved in cerebrospinal
fluid production and osmoregulation, suggesting it could be
involved in beneficial effects of P4 on the blood-brain barrier and
osmoregulation following TBI (Meffre et al., 2005).
PGRMC1 is expressed in the plasma membrane and other cel-
lular locations (Falkenstein et al., 1999; Sakamoto et al., 2004;
Peluso, 2006). Progesterone and other steroids bind to PGRMC1
in membrane fractions (Falkenstein et al., 1999), but whether P4
actually binds to and signals through PGRMC1 has been ques-
tioned (Cahill, 2007; Price, 2013). ALLO binding to PGRMC1 has
not been analyzed. Interestingly, PGRMC1 protein levels were up-
regulated in neurons and were induced at the site of injury in
astrocytes after TBI (Meffre et al., 2005). It has been hypothe-
sized that P4 protects the brain after injury by up-regulating brain
derived neurotrophic factor (BDNF), a neurotrophin known to
promote survival of neurons and play a role in cognition, anxiety-
like behavior and pain (Gonzalez et al., 2005). In glial cells,
P4 acts through PGRMC1 to increase BDNF (Su et al., 2012).
Furthermore, a role for PGRMC1 in synaptogenesis of developing
Purkinje cells in neonatal rats has been suggested (Sakamoto et al.,
2004). Treatment with P4 after spinal cord injury up-regulates
PGRMC1 without affecting Pgr expression, and this neuropro-
tective role of P4 acting through PGRMC1 could also occur in
brain following TBI (Labombarda et al., 2003; Guennoun et al.,
2008).
Increased proliferation of neuroprogenitor cells from adult
rat hippocampus induced by P4 is mediated through PGRMC1
because these cells lack Pgr and proliferation was prevented by
inhibiting PGRMC1 mRNA (Liu et al., 2009). Various reports
suggest PGRMC1 might mediate P4 effects on axonal regenera-
tion and growth (Runko and Kaprielian, 2004; Sakamoto et al.,
2004) and promote survival of neuronal cells (Gonzalez et al.,
2005) by preventing apoptosis after TBI. Studies using global and
brain-specific PGRMC1 knockout mice will be useful to establish
the role of PGRMC1 in P4 and ALLO effects.
A number of other mPRs have been described that are struc-
turally distinct from PGRMC1, but have significant homology
with each other. These mPRs were discovered in fish oocytes
and then later reported in other vertebrates including humans
(Zhu et al., 2003a,b). Five mPR subtypes have been characterized:
mPRα, mPRβ, and mPRγ are coupled to inhibitory G-proteins
and inhibit intracellular cAMP generation while mPRδ andmPRε
are coupled to stimulatory G proteins and increase intracellular
cAMP (Pang et al., 2013). P4 and its metabolites including ALLO
bind mPRs and initiate signaling (Thomas and Pang, 2012).
www.frontiersin.org June 2013 | Volume 7 | Article 108 | 5
Cooke et al. Progesterone and traumatic brain injury
Expression of mPRs is extensive in the rat, mouse and human
brain (Intlekofer and Petersen, 2011; Zuloaga et al., 2012; Meffre
et al., 2013; Pang et al., 2013), but the role of these mPRs (if
any) in mediating protective effects of P4 and ALLO after TBI
is unclear. Among the mPRs, mPRα is the most studied and
mediates numerous P4 effects in fish (Zhu et al., 2003b; Tubbs
and Thomas, 2009; Dressing et al., 2010), but also has effects
on human breast cancer cells (Dressing et al., 2012) and GnRH
release from rodent GnRH neurons (Sleiter et al., 2009). In
rodents, mPRα was localized in the neurons, but not the glia,
of normal animals. However, mPRα expression was induced in
glial cells (oligodendrocytes, astrocytes, and reactive microglia)
after TBI. These observations led the authors to conclude that
mPRα may play a role in mediating neuroprotective effects of
P4 (Zuloaga et al., 2012). Furthermore, P4 and ALLO prevented
apoptosis and death of serum-deprived immortalized GnRH
secreting neurons that express high levels of mPRs (α, β, δ, ε) but
negligible levels of Pgr (Thomas and Pang, 2012). Recently, P4
and ALLO were reported to inhibit starvation-induced cell death
and apoptosis in rat hippocampal neuronal cells that show higher
levels mPRδ and mPRε mRNAs compared to mPRα and mPRβ
and relatively low Pgr expression (Pang et al., 2013). These results
suggest possible neuroprotective roles of mPRs in mediating P4
and ALLO effects after TBI, but whether mPRs are involved in
neuroprotective effects of P4 and ALLO, as well as the poten-
tial specific roles of the various mPR subtypes, remains to be
established.
In summary, protective roles of P4 and ALLO may involve sig-
naling through a number of non-classical receptors, in addition
to Pgr. Elucidating these mechanisms of action will advance our
understanding of the roles of P4 and its metabolites in normal
brain function, as well as shed light on the therapeutic pos-
sibilities of these compounds for treatment of TBI and other
neurodegenerative diseases.
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